Related Experiment Videos
Oxygen-induced retinopathy in the mouse
L E Smith1, E Wesolowski, A McLellan
1Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
Investigative Ophthalmology & Visual Science
|January 1, 1994
Summary
This study developed a reproducible mouse model for oxygen-induced retinopathy, enabling better research into retinal neovascularization and treatments for conditions like retinopathy of prematurity.
Area of Science:
- Ophthalmology
- Vascular Biology
- Developmental Biology
Background:
- Retinal neovascularization is a hallmark of several serious eye conditions, including retinopathy of prematurity (ROP).
- Developing reliable animal models is crucial for understanding the pathogenesis and testing therapies for these diseases.
Purpose of the Study:
- To establish a reproducible and quantifiable mouse model of oxygen-induced retinopathy.
- To create a model suitable for studying the mechanisms and potential treatments of retinal neovascularization.
Main Methods:
- One-week-old C57BL/6J mice were exposed to hyperoxia (75% oxygen) followed by room air.
- A novel fluorescein-dextran perfusion method was employed for vascular assessment.
- Neovascularization was quantified by counting nuclei in retinal cross-sections and assessed for glial fibrillary acidic protein (GFAP) association.
Main Results:
- The fluorescein-dextran method effectively visualized neovascular tufts in flat-mounted retinas.
- Oxygen-induced neovascularization occurred at the vascular-avascular junction in the retinal mid-periphery.
- A significant increase in neovascular nuclei was observed in hyperoxia-exposed mice compared to controls (mean 89 vs. <1, P < 0.0001).
- Proliferative vessels were not associated with GFAP-positive astrocytes.
Conclusions:
- A reproducible and quantifiable mouse model for oxygen-induced retinal neovascularization has been developed.
- This model is valuable for investigating the pathogenesis of retinal neovascularization.
- The model is suitable for evaluating therapeutic interventions for retinopathy of prematurity and other retinal angiopathies.